NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
POLYCILLIN-N (ampicillin sodium) by Bristol Myers Squibb is clinical pharmacology general immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYCILLIN-N is an intravenous antibiotic combination of ampicillin sodium and sulbactam, a beta-lactamase inhibitor that restores ampicillin activity against resistant bacteria. It is indicated for infections caused by beta-lactamase-producing organisms across respiratory, urinary, skin, and intra-abdominal sites. The drug works by inhibiting bacterial cell wall synthesis while protecting ampicillin from enzymatic degradation.
Pre-Launch
Pre-launch stage indicates active commercial planning and team expansion; career roles will focus on launch preparation, market access, and competitive positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of…
Worked on POLYCILLIN-N at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.